
-
Russian fuel prices surge after Ukraine hits refineries
-
Maguire feels it will be 'silly' to leave Man Utd now
-
Ukrainian suspect arrested in Italy over Nord Stream blasts
-
England include ex-skipper Knight in Women's World Cup squad as Cross misses out
-
Walmart lifts outlook for sales, earnings despite tariffs
-
UK sees record asylum claims as row brews over housing
-
Swiss international Okafor move to Leeds heralds new EPL record
-
Microsoft re-joins handheld gaming fight against Nintendo's Switch
-
McReight to captain Wallabies against Springboks
-
Taiwanese boxer Lin agrees to gender test for world championships
-
Stocks slip as investors await key Fed speech
-
Hong Kong mogul Jimmy Lai's 'punditry' not criminal: lawyer
-
Bournemouth sign 'proven winner' Adli from Leverkusen
-
Israel pounds Gaza City as military takes first steps in offensive
-
First security guarantees, then Putin summit, Zelensky says
-
Suspended Thai PM testifies in court case seeking her ouster
-
Shilton congratulates Brazilian goalkeeper Fabio on breaking record
-
Markets mixed as investors await key Fed speech
-
Israel pounds Gaza City after offensive gets green light
-
Fraser-Pryce seeks Brussels boost ahead of Tokyo worlds
-
Asian markets mixed as investors await key speech
-
Ten hurt, 90 arrested as match abandoned following fan violence in Argentina
-
Indian heritage restorers piece together capital's past
-
Australian Rules player suspended for homophobic slur
-
Online behaviour under scrutiny as Russia hunts 'extremists'
-
Malaysia rules out return of F1 over costs
-
German firm gives 'second life' to used EV batteries
-
Wallabies great Will Genia announces retirement at 37
-
South Africa spinner Subrayen cited for suspect bowling action
-
Menendez brothers face parole board seeking freedom after parents murders
-
Weaponising the feed: Inside Kenya's online war against activists
-
Africa could become 'renewable superpower', says Guterres
-
Suspended Thai PM in court for case seeking her ouster
-
Errani, Vavassori retain US Open mixed doubles title in revamped event
-
Surging tourism is polluting Antarctica, scientists warn
-
Ten Hag hoping for fresh start at rebuilding Leverkusen
-
Five players to watch at the Women's Rugby World Cup
-
Suarez fills Messi void as Inter Miami beat Tigres 2-1
-
Asian markets creep up as investors await key speech
-
New Zealand spy service warns of China interference
-
Brazil police accuse Bolsonaro and son of obstructing coup trial
-
Israel approves major West Bank settlement project
-
North Carolina braces for flooding from Hurricane Erin
-
Pensioners on the frontline of Argentina's fiery politics
-
'Curly is beautiful': Tunisian women embrace natural hair
-
Sudanese lay first bricks to rebuild war-torn Khartoum
-
Newcastle host Liverpool amid Isak stand-off, Spurs test new-look Man City
-
Texas Republicans advance map that reignited US redistricting wars
-
South Africa spinner Subrayen cited for suspect action
-
Meme-lord Newsom riles Republicans with Trump-trolling posts

Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:
Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at 10:00am ET
Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25th at 10:30am ET
A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website.
A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
P.Costa--AMWN